<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3009245991
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Litfulo
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        RITLECITINIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        3605.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Pfizer Manufacturing Deutschland GmbH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Pfizer Manufacturing Deutschland GmbH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            PFIZER INC
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04A-IMMUNOSUPPRESSANTS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Litfulo contains the active substance ritlecitinib. It is used to treat severe alopecia areata in adults and adolescents 12&nbsp;years of age and older. Alopecia areata is a disease where the body&rsquo;s own immune system attacks hair follicles, causing inflammation that leads to hair loss on the scalp, face and/or other parts of the body.&nbsp;</p><p>&nbsp;</p><p>Litfulo works by reducing the activity of enzymes called JAK3 and TEC kinases, which are involved in inflammation at the hair follicle. This reduces the inflammation, leading to hair regrowth in patients with alopecia areata.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><em>&nbsp;</em></p><p><strong>Do not take Litfulo</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to ritlecitinib or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a serious infection ongoing, including tuberculosis.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe liver problems.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are pregnant or breast-feeding (see the &ldquo;pregnancy, contraception, breast‑feeding and fertility&rdquo; section).</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor or pharmacist before and during treatment with Litfulo if you<strong>: </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have an infection (possible signs may be fever, sweating, chills, muscle aches, cough, shortness of breath, blood in your phlegm, weight loss, diarrhoea, stomach pain, burning when you urinate, urinating more often than usual, feeling very tired). Litfulo can reduce your body&rsquo;s ability to fight infections and so worsen an existing infection or make it more likely for you to get a new infection.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have diabetes or are older than 65 years of age, you may have an increased risk of getting infections.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have, or have had, tuberculosis or have been in close contact with someone with tuberculosis, or if you reside or travel in regions where tuberculosis is very common. Your doctor will test you for tuberculosis before starting Litfulo and may retest you during treatment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have ever had a herpes infection (such as chickenpox or shingles), because Litfulo may allow it to come back. Tell your doctor if you get a painful skin rash with blisters as this can be a sign of shingles.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have ever had hepatitis B or hepatitis C. Your doctor will test you for hepatitis before starting Litfulo and may retest you during treatment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have cancer or have had any cancer &ndash; it is not clear if Litfulo increases the risk of cancer, and your doctor will discuss with you if treatment with this medicine is appropriate and whether check-ups including regular skin checks will be necessary during treatment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have had blood clots in the veins of your legs (deep vein thrombosis) or lungs (pulmonary embolism). Tell your doctor if you get a painful swollen leg, chest pain, or shortness of breath as these can be signs of blood clots in the veins.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have had blood clots in an artery in the eye (retinal occlusion) or heart (heart attack). Tell your doctor if you experience acute changes to your eyesight (blurry vision, partial or complete loss of vision), chest pain, shortness of breath as these changes may be a sign of blood clots in the arteries.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have recently had or plan to have a vaccination (immunisation) &ndash; this is because certain vaccines (live vaccines) are not recommended while using Litfulo. Check with your doctor to see if your vaccinations are up to date and if you require additional vaccinations, including vaccination for shingles, before treatment with Litfulo.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have unexplained symptoms caused by a problem with the nervous system while taking Litfulo. Your doctor will discuss with you if treatment should be discontinued.</p><p>&nbsp;</p><p><u>Additional monitoring tests</u></p><p><u>&nbsp;</u></p><p>Your doctor will carry out blood tests to check if you have low white blood cell count or low platelet count before and approximately 4 weeks after starting Litfulo treatment and may adjust your treatment if necessary.</p><p>&nbsp;</p><p><strong>Children </strong></p><p>This medicine is not approved for use in children below the age of 12&nbsp;years because the safety and benefits of Litfulo are not established in this age group.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Litfulo</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>In particular, tell your doctor or pharmacist before taking Litfulo if you are taking some of the medicines to treat:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anxiety or sleep disorders (such as midazolam),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart rhythm problems (such as quinidine),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gout (such as colchicine),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rejection in organ transplantation (such as cyclosporine, everolimus, tacrolimus and sirolimus),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; migraine (such as dihydroergotamine and ergotamine),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; schizophrenia and chronic psychosis (such as pimozide),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; asthma (such as theophylline),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle spasms (such as tizanidine),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; idiopathic pulmonary fibrosis (such as pirfenidone).</p><p>&nbsp;</p><p>Litfulo may increase the amount of these medicines in your blood.</p><p>&nbsp;</p><p>If any of the above apply to you or if you are not sure, talk to your doctor or pharmacist before taking Litfulo.</p><p>&nbsp;</p><p><strong>Pregnancy, contraception, breast-feeding and fertility</strong></p><p>If you are pregnant or breast‑feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><u>Contraception in women</u></p><p><u>&nbsp;</u></p><p>If you are a woman of childbearing potential, you should use an effective method of contraception during treatment with Litfulo, and for at least one month after your last treatment dose. Your doctor can advise you on suitable methods of contraception.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p><u>&nbsp;</u></p><p>Do not use Litfulo if you are pregnant, think you may be pregnant or are planning to have a baby. This medicine can harm the developing baby. Tell your doctor right away if you become pregnant or think you might have become pregnant during treatment.</p><p>&nbsp;</p><p><u>Breast‑feeding</u></p><p><u>&nbsp;</u></p><p>Do not use Litfulo while breast-feeding as it is not known if this medicine passes into breast milk or if breast-fed babies are affected. You and your doctor should decide if you will breast-feed or use this medicine.</p><p>&nbsp;</p><p><u>Fertility</u></p><p><u>&nbsp;</u></p><p>It is unknown if Litfulo reduces fertility in women or men of childbearing potential.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Litfulo has no or limited effect on the ability to drive or use machines.</p><p>&nbsp;</p><p><strong>Litfulo contains lactose </strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>The recommended dose is 50&nbsp;mg once a day taken by mouth.&nbsp;</p><p>&nbsp;</p><p>You should swallow your capsule whole with water. Do not open, crush or chew the capsule before swallowing as it may change how much medicine gets into your body.</p><p>&nbsp;</p><p>You can take the capsule either with or without food.</p><p>&nbsp;</p><p><strong>If you take more Litfulo than you should</strong></p><p>If you take more Litfulo than you should, contact your doctor. You may get some of the side effects described in section 4.</p><p><em>&nbsp;</em></p><p><strong>If you forget to take Litfulo</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you miss a dose, take it as soon as you remember, unless your next dose is due in less than 8&nbsp;hours.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If there is less than 8&nbsp;hours before your next dose, just skip the missed dose and take your next dose as usual when it is due.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take a double dose to make up for a forgotten capsule.</p><p>&nbsp;</p><p><strong>If you stop taking Litfulo</strong></p><p>You should not stop taking Litfulo without discussing this with your doctor.</p><p>&nbsp;</p><p>If you need to stop taking Litfulo for a short time (not more than 6 weeks), the risk of losing your scalp hair is low.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong><u>Serious side effects</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p>Talk to your doctor and get medical help straight away if you get any signs of:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shingles (herpes zoster), a painful skin rash with blisters with or without fever</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hives (urticaria), an itching skin rash</p><p><strong>&nbsp;</strong></p><p><strong><u>Other side effects</u></strong></p><p><strong>&nbsp;</strong></p><p><strong>Common </strong>(may affect up to 1 in 10 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections of nose, throat or the windpipe</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acne</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash (other than hives and shingles)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation (swelling) of the hair follicles which may be itchy or painful (folliculitis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase in an enzyme called creatine phosphokinase, shown by blood test (blood creatine phosphokinase increased)</p><p>&nbsp;</p><p><strong>Uncommon</strong> (may affect up to 1 in 100 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low platelet count shown by blood test (platelet count decreased)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low white blood cell count shown by blood test (lymphocyte count decreased)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase of liver enzymes in the blood (ALT and AST increased)</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p><strong>&nbsp;</strong></p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp; Call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton, bottle, or blister after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store LITFULO below 30&deg;C.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is ritlecitinib.</p><p>Each hard capsule contains ritlecitinib tosylate equivalent to 50&nbsp;mg ritlecitinib.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>Hard capsule content: cellulose microcrystalline, lactose monohydrate, crospovidone ), glycerol dibehenate (see section 2 &ldquo;Litfulo contains lactose monohydrate&rdquo;).</p><p>Hard capsule shell: hypromellose (E464), titanium dioxide (E171), yellow iron oxide (E172), brilliant blue FCF (E133).</p><p>Printing ink: shellac, propylene glycol, ammonia solution concentrated, black iron oxide (E172), potassium hydroxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Litfulo 50 mg opaque hard capsules have a yellow body and blue cap approximately 16 mm long and 6 mm wide of which the body is printed with “RCB 50” and the cap is printed with “Pfizer” in black.

The 50 mg hard capsules are provided in OPA/Al/PVC/Al blisters containing 30 hard capsules. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Pfizer Inc.<br />New York, USA</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                ..
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي ليتفولو على المادة الفعالة ريتليسيتينيب. وهو يُستخدم لعلاج الثعلبة البقعية الشديدة لدى البالغين والمراهقين من عمر ۱۲ عامًا فأكبر. الثعلبة البقعية مرض يهاجم فيه الجهاز المناعي للجسم بصيلات الشعر، مما يتسبب في حدوث التهابات تؤدي إلى تساقط الشعر من فروة الرأس، و/أو الوجه، و/أو أجزاء أخرى من الجسم.&nbsp;</p><p>&nbsp;</p><p dir="RTL">ويعمل ليتفولو عن طريق تقليل نشاط الإنزيمات التي تسمى جانوس كيناز ۳ (JAK3) وكينازات بروتين تيروزين (TEC) التي تشارك في حدوث التهاب في بصيلات الشعر. ويقلل ذلك من الالتهابات، مما يؤدي إلى إعادة نمو الشعر لدى المرضى الذين يعانون من الثعلبة البقعية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><em>&nbsp;</em></p><p dir="RTL"><strong>موانع استعمال ليتفولو</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية تجاه ريتليسيتينيب أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم ٦).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من عدوى خطيرة مستمرة، بما في ذلك السل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلات شديدة في الكبد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية (انظري قسم &quot;الحمل والرضاعة&quot;).</p><p>&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال ليتفولو</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل وأثناء العلاج بليتفولو إذا<strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مصابًا بعدوى (قد تكون العلامات المحتملة الحمى، التعرق، القشعريرة، أوجاع العضلات، السعال، ضيق التنفس، وجود الدم في البلغم، فقدان الوزن، الإسهال، ألم المعدة، الشعور بحرقان عند التبول، التبول بشكل أكبر من المعتاد، الشعور بالتعب الشديد). يمكن أن يقلل ليتفولو من قدرة جسمك على مكافحة العدوى وبالتالي يؤدي إلى تفاقم حالة العدوى الموجودة أو يُزيد من احتمالية إصابتك بعدوى جديدة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بداء السكري وعمرك يزيد عن ٦٥ عامًا، فقد تكون عرضة بشكل متزايد لخطر الإصابة بحالات العدوى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مصابًا بالسل حاليًا، أو سبق أن أُصبت به، أو خالطت عن قرب شخصًا مصابًا بالسل، أو إذا كنت تقيم أو تسافر في مناطق يكون فيها السل شديد الانتشار. سيُجري طبيبك اختبارًا للكشف عن إصابتك بالسل قبل بدء العلاج بليتفولو، وقد يعيد إجراء الاختبار عليك أثناء تلقي العلاج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سبقت لك الإصابة بعدوى هربس (مثل جدري الماء أو الحلأ النطاقي)، لأن تناول ليتفولو قد يؤدي إلى الإصابة بها مجددًا. أخبر طبيبك إذا أُصبت بطفح جلدي مؤلم مع وجود بثور، فقد تكون هذه علامات على الإصابة بالحلأ النطاقي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سبقت لك الإصابة بالتهاب الكبد الوبائي B أو التهاب الكبد الوبائي C. سيُجري طبيبك اختبارًا للكشف عن إصابتك بالتهاب الكبد الوبائي قبل بدء العلاج بليتفولو، وقد يعيد إجراء الاختبار عليك أثناء تلقي العلاج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مصابًا بالسرطان أو سبقت لك الإصابة بأي سرطانات &ndash; فليس من الواضح ما إذا كان ليتفولو يُزيد من خطر الإصابة بالسرطان، وسيناقش طبيبك معك ما إذا كان العلاج بهذا الدواء يعد مناسبًا وما إذا كان من الضروري إجراء فحوصات، بما في ذلك الفحوصات الجلدية العادية، أثناء العلاج أم لا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سبقت لك الإصابة بجلطات دموية في أوردة ساقيك (الخثار الوريدي العميق) أو رئتيك (الانصمام الرئوي). أخبر طبيبك إذا أُصبت بتورم مؤلم في الساق، أو ألم الصدر، أو ضيق التنفس، فقد تكون هذه علامات على وجود جلطات دموية في الأوردة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سبقت لك الإصابة بجلطات دموية في أحد شرايين العين (انسداد الشرايين الشبكي) أو القلب (النوبة القلبية). وأخبر طبيبك إذا كنت تعاني من تغيرات حادة في بصرك (تغيم الرؤية، فقدان جزئي أو كامل للرؤية)، ألم الصدر، ضيق التنفس لأن هذه التغيرات قد تكون علامة على وجود جلطات دموية في الشرايين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت قد تلقيت لقاحًا مؤخرًا أو تخطط لتلقي لقاح (تطعيم) &ndash; وذلك لأنه لا يوصى بتلقي لقاحات معينة (اللقاحات الحية) أثناء استخدام ليتفولو. واستشر طبيبك لمعرفة ما إذا كانت اللقاحات التي تتلقاها حديثة وما إذا كنت بحاجة إلى لقاحات إضافية، بما في ذلك لقاح الحلأ النطاقي، قبل العلاج بليتفولو.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك أعراض غير معروفة السبب ناتجة عن حدوث مشكلة في الجهاز العصبي أثناء تناول ليتفولو. سيناقش طبيبك معك ما إذا كان ينبغي التوقف عن تلقي العلاج.</p><p>&nbsp;</p><p dir="RTL"><u>اختبارات المراقبة الإضافية</u></p><p><u>&nbsp;</u></p><p dir="RTL">سيقوم طبيبك بإجراء فحوصات الدم للتحقق مما إذا كان لديك انخفاض في تعداد خلايا الدم البيضاء أو انخفاض في تعداد الصفائح الدموية قبل وبعد ٤ أسابيع تقريبًا من بدء العلاج بليتفولو، وقد يعدِّل العلاج إذا لزم الأمر.</p><p>&nbsp;</p><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL">هذا الدواء غير مصرح باستخدامه لدى الأطفال الذين تقل أعمارهم عن ۱۲ عامًا لأن سلامة وفوائد ليتفولو غير مثبتة في هذه الفئة العمرية.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>التداخلات الدوائية مع أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول حاليًا، أو تناولت مؤخرًا، أو قد تتناول أي أدوية أخرى.</p><p>&nbsp;</p><p dir="RTL">وتحديدًا، أخبر طبيبك أو الصيدلي قبل تناول ليتفولو إذا كنت تتناول بعض الأدوية لعلاج:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق أو اضطرابات النوم (مثل ميدازولام)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات متعلقة بنظم القلب (مثل كينيدين)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النقرس (مثل كولشيسين)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رفض الجسم للعضو المزروع (مثل سيكلوسبورين، وإيفيروليموس، وتاكروليموس، وسيروليموس)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع النصفي (مثل داي هيدروإرجوتامين، وإرجوتامين)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفصام والذهان المزمن (مثل بيموزيد)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الربو (مثل ثيوفيلين)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنج العضلات (مثل تيزانيدين)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التليف الرئوي مجهول السبب (مثل بيرفنيدون).</p><p>&nbsp;</p><p dir="RTL">قد يُزيد ليتفولو من كمية هذه الأدوية في دمك.</p><p>&nbsp;</p><p dir="RTL">إذا كان أي مما ورد أعلاه ينطبق عليك أو إذا لم تكن متأكدًا، فتحدث إلى طبيبك أو الصيدلي قبل تناول ليتفولو.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong><strong> </strong><strong>و</strong> <strong> الخصوبة</strong></p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية، أو تعتقدين أنكِ ربما تكونين حاملًا، أو تخططين للإنجاب، فاستشيري طبيبكِ أو الصيدلي قبل تناول هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><u>منع الحمل لدى السيدات</u></p><p><u>&nbsp;</u></p><p dir="RTL">إذا كنتِ سيدة قادرة على الإنجاب، ينبغي أن تستخدمي وسيلة فعالة لمنع الحمل أثناء فترة العلاج بليتفولو ولمدة شهر واحد على الأقل بعد تلقي آخر جرعة من العلاج. يمكن لطبيبكِ تقديم المشورة إليكِ بشأن وسائل منع الحمل المناسبة.</p><p>&nbsp;</p><p dir="RTL"><u>الحمل</u></p><p><u>&nbsp;</u></p><p dir="RTL">لا تتناولي ليتفولو إذا كنتِ حاملًا أو تعتقدين أنكِ ربما تكونين حاملًا أو تخططين للحمل. يمكن أن يضر هذا الدواء الجنين في مرحلة النمو. أخبري طبيبك على الفور إذا أصبحتِ حاملًا أو كنتِ تعتقدين أنكِ ربما أصبحتِ حاملًا أثناء العلاج.</p><p>&nbsp;</p><p dir="RTL"><u>الرضاعة الطبيعية</u></p><p><u>&nbsp;</u></p><p dir="RTL">لا تستخدمي ليتفولو خلال فترة الرضاعة الطبيعية لأنه من غير المعروف ما إذا كان هذا الدواء يمر إلى لبن الثدي أو يؤثر على الأطفال الذين يرضعون رضاعة طبيعية أم لا. ينبغي أن تقرري أنتِ وطبيبكِ ما إذا كنتِ سترضعين رضاعة طبيعية أم ستستخدمين هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><u>الخصوبة</u></p><p><u>&nbsp;</u></p><p dir="RTL">إنه من غير المعروف ما إذا كان ليتفولو يقلل الخصوبة لدى السيدات والرجال القادرين على الإنجاب.</p><p>&nbsp;</p><p dir="RTL"><strong>تأثير ليتفولو على القيادة واستخدام الآلات</strong></p><p dir="RTL">ليتفولو ليس له تأثير أو له تأثير محدود على القدرة على القيادة واستخدام الآلات.</p><p>&nbsp;</p><p dir="RTL"><strong>يحتوي ليتفولو على اللاكتوز</strong></p><p dir="RTL">إذا أخبرك طبيبك أنك لا تستطيع تحمل بعض أنواع السكريات، فتواصل مع طبيبك قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على تناول هذا الدواء تمامًا كما أخبرك طبيبك. وارجع إلى طبيبك أو الصيدلي إذا لم تكن متأكدًا مما ينبغي لك فعله.</p><p>&nbsp;</p><p dir="RTL">الجرعة الموصى بها هي ٥٠ ملجم مرة واحدة في اليوم عن طريق الفم.&nbsp;</p><p>&nbsp;</p><p dir="RTL">ينبغي أن تبتلع الكبسولة كاملةً بالماء. لا تفتح الكبسولة أو تسحقها أو تمضغها قبل ابتلاعها لأن ذلك قد يغير كمية الدواء التي تدخل في جسمك.</p><p>&nbsp;</p><p dir="RTL">يمكنك تناول الكبسولة مع الطعام أو دونه.</p><p>&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من ليتفولو</strong></p><p dir="RTL">إذا تناولت كمية أكبر مما ينبغي من ليتفولو، فتواصل مع طبيبك. قد تصاب ببعض الأعراض الجانبية الموضحة في القسم ٤.</p><p><em>&nbsp;</em></p><p dir="RTL"><strong>نسيان تناول جرعة ليتفولو</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا فاتتك إحدى الجرعات، فتناولها بمجرد أن تتذكر ما لم يكن موعد جرعتك التالية بعد أقل من ٨ ساعات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت الفترة المتبقية حتى موعد جرعتك التالية تقل عن ٨ ساعات، فتخط الجرعة الفائتة وتناول جرعتٍك التالية في موعدها المعتاد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول جرعة مضاعفة لتعويض الكبسولة التي نسيت تناولها.</p><p>&nbsp;</p><p dir="RTL"><strong>التوقف عن تناول ليتفولو</strong></p><p dir="RTL">ينبغي ألا تتوقف عن تناول ليتفولو دون مناقشة ذلك مع طبيبك.</p><p>&nbsp;</p><p dir="RTL">إذا كنت بحاجة إلى التوقف عن تناول ليتفولو لوقت قصير (لا يزيد عن ٦ أسابيع)، فإن خطر فقدانك لشعر فروة رأسك يكون قليلًا.</p><p>&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، رغم أنها لا تصيب الجميع.</p><p>&nbsp;</p><p dir="RTL"><strong><u>الأعراض الجانبية الخطيرة</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p dir="RTL">تحدث إلى طبيبك واطلب المساعدة الطبية على الفور إذا ظهرَت عليك أي علامات للإصابة بما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحلأ النطاقي (الهربس النطاقي)، وهو طفح جلدي مؤلم مصحوب بثور مع أو دون حمى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشرى (ارتيكاريا)، وهو طفح جلدي مسبب للحكة</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong><u>الأعراض الجانبية الأخرى</u></strong></p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة </strong>(قد تصيب ما يصل إلى شخص واحد من بين كل ١٠ أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الأنف أو الحلق أو القصبة الهوائية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حب الشباب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي (بخلاف الشرى والحلأ النطاقي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب (تورم) بصيلات الشعر الذي قد يكون مسببًا للحكة أو مؤلمًا (التهاب الجريبات)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في الإنزيم المعروف باسم فوسفوكيناز الكرياتين، وتظهر في فحص الدم (ارتفاع مستوى فوسفوكيناز الكرياتين في الدم)</p><p>&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong> (قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠ شخص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض تعداد الصفائح الدموية يظهره فحص الدم (انخفاض تعداد الصفائح الدموية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض تعداد خلايا الدم البيضاء يظهره فحص الدم (انخفاض تعداد الليمفاويات)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى إنزيمات الكبد في الدم (ارتفاع كل من ناقلة أمين الألانين (ALT) وناقلة أمين الأسبارتات (AST))</p><p>&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا أصبت بأي أعراض جانبية، فتحدث إلى طبيبك أو الصيدلي. ويتضمن ذلك أي أعراض جانبية محتملة غير مذكورة في هذه النشرة. بالإبلاغ عن الأعراض الجانبية، يمكنك المساعدة في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p>&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية</strong></p><p>&nbsp;</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp; </em>مركز الاتصال الموحد: ۱۹۹۹۹</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى</strong></p><p><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp; </em><em>الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</em></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية أو الزجاجة أو شريط بليستر بعد رمز انتهاء الصلاحية &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p>&nbsp;</p><p dir="RTL">&rlm;يُحفظ ليتفولو في درجة حرارة أقل من ٣٠ درجة مئوية.</p><p>&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو مع النفايات المنزلية. واسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي ريتليسيتينيب.</p><p dir="RTL">تحتوي كل كبسولة صلبة على ريتليسيتينيب توسيلات بما يعادل ٥٠ ملجم من ريتليسيتينيب.</p><p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL">مكونات الكبسولة الصلبة: سليولوز دقيق التبلور، لاكتوز أحادي الهيدرات، كروسبوفيدون، ديبهينات الجلسرين (انظر القسم ٢ &quot;يحتوي ليتفولو على اللاكتوز&quot;).</p><p dir="RTL">غلاف الكبسولة الصلبة: هيبروميلوز (E464)، ثنائي أكسيد التيتانيوم (E171)، أكسيد الحديد الأصفر (E172)، صبغة زرقاء لامعة FCF &rlm;(E133).</p><p dir="RTL">حبر الطباعة: صمغ اللك، بروبيلين جليكول، محلول الأمونيا المركز، أكسيد الحديد الأسود (E172)، هيدروكسيد البوتاسيوم.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كبسولات ليتفولو ٥۰ ملجم الصلبة غير الشفافة لها جسم أصفر وغطاء أزرق، بطول ١٦ مم وعرض ٦ مم تقريبًا ومطبوع على الجسم كلمة &quot;RCB 50&quot; ومطبوع على الغطاء كلمة &quot;Pfizer&quot; باللون الأسود.</p><p>&nbsp;</p><p dir="RTL">تتوفر كبسولات ٥۰ ملجم الصلبة في شرائط بليستر من البولي أميد الموجه (OPA)/الألمونيوم (Al)/بولي فينيل كلوريد (PVC)/الألمونيوم تحتوي على ۳۰ كبسولة صلبة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق</strong></p><p dir="RTL">فايزر انك<br />نيويورك، الولايات المتحدة الأمريكية</p><p>&nbsp;</p><p dir="RTL"><strong>المصنع</strong></p><p dir="RTL">فايزر مانفاكشرينق ديتشلاند جي ام بي اتش</p><p dir="RTL">فرييبرج، ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ..
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Litfulo 50 mg hard capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each hard capsule contains ritlecitinib tosylate equivalent to 50 mg ritlecitinib. 

Excipient(s) with known effect

Each hard capsule contains 21.27 mg of lactose monohydrate. 

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsule (capsule)

Opaque hard capsules, yellow body and blue cap approximately 16 mm long and 6 mm wide, of which the body is printed with “RCB 50” and the cap is printed with “Pfizer” in black.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12&nbsp;years of age and older (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment should be initiated and supervised by a healthcare professional experienced in the diagnosis and treatment of alopecia areata.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>The recommended dose is 50&nbsp;mg once daily.</p><p>&nbsp;</p><p>The benefit-risk of treatment should be re-assessed at regular intervals on an individual basis.</p><p>&nbsp;</p><p>Consideration should be given to discontinuing patients who show no evidence of therapeutic benefit after 36&nbsp;weeks. &nbsp;&nbsp;</p><p><em>&nbsp;</em></p><p><em>Laboratory monitoring</em></p><p>&nbsp;</p><p>Table 1.&nbsp;&nbsp;&nbsp; Laboratory measures and monitoring guidance</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Laboratory measures</p></td><td style="vertical-align:top"><p>Monitoring guidance</p></td><td style="vertical-align:top"><p>Action</p></td></tr><tr><td style="vertical-align:top"><p>Platelet count</p></td><td rowspan="2"><p>Before treatment initiation, 4&nbsp;weeks after initiation, and thereafter according to routine patient management.</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Treatment should be discontinued if platelet count is &lt;&nbsp;50&nbsp;&times;&nbsp;10<sup>3</sup>/mm<sup>3</sup>.</p></td></tr><tr><td style="vertical-align:top"><p>Lymphocytes</p></td><td style="vertical-align:top"><p>Treatment should be interrupted if ALC is &lt;&nbsp;0.5&nbsp;&times;&nbsp;10<sup>3</sup>/mm<sup>3</sup> and may be restarted once ALC return above this value.</p></td></tr></tbody></table><p>Abbreviation: ALC = absolute lymphocyte count</p><p>&nbsp;</p><p><em>Treatment initiation</em></p><p>Treatment with ritlecitinib should not be initiated in patients with an absolute lymphocyte count (ALC) &lt;&nbsp;0.5&nbsp;<strong>&times;&nbsp;</strong>10<sup>3</sup>/mm<sup>3</sup> or a platelet count &lt;&nbsp;100&nbsp;<strong>&times;&nbsp;</strong>10<sup>3</sup>/mm<sup>3 </sup>(see section 4.4).</p><p>&nbsp;</p><p><em>Treatment interruption or discontinuation</em></p><p>If a patient develops a serious infection or opportunistic infection, ritlecitinib should be interrupted until the infection is controlled (see section 4.4).</p><p>&nbsp;</p><p>Interruption or discontinuation of treatment may be needed for management of haematologic abnormalities as described in Table 1.</p><p>&nbsp;</p><p>If treatment interruption is needed, the risk of significant loss of regrown scalp hair after a temporary treatment interruption for less than 6&nbsp;weeks is low.</p><p>&nbsp;</p><p><em>Missed doses</em></p><p>If a dose is missed, patients should be advised to take the dose as soon as possible unless it is less than 8&nbsp;hours before the next dose, in which case the patient should not take the missed dose. Thereafter, dosing should be resumed at the regular scheduled time.</p><p><em>&nbsp;</em></p><p><u>Special populations</u></p><p><em>&nbsp;</em></p><p><em>Renal impairment</em><em> </em></p><p>No dose adjustment is required in patients with mild, moderate, or severe renal impairment (see section 5.2).</p><p>&nbsp;</p><p>Ritlecitinib has not been studied in patients with end‑stage renal disease (ESRD) or in patients with renal transplants and is therefore not recommended for use in these patients.</p><p>&nbsp;</p><p><em>Hepatic impairment</em><em> </em></p><p>No dose adjustment is required in patients with mild (Child Pugh A) or moderate (Child Pugh B) hepatic impairment (see section 5.2). Ritlecitinib is contraindicated in patients with severe (Child Pugh C) hepatic impairment (see section 4.3).</p><p><em>&nbsp;</em></p><p><em>Elderly</em></p><p>No dose adjustment is required for patients &ge;&nbsp;65&nbsp;years of age. There are limited data in patients &ge;&nbsp;65&nbsp;years of age.</p><p><em>&nbsp;</em></p><p><em>Pediatric population</em></p><p>No dose adjustment is required for adolescents 12 to &lt;&nbsp;18&nbsp;years of age.</p><p>&nbsp;</p><p>The safety and efficacy of Litfulo in children under 12&nbsp;years of age have not yet been established. No data are available.</p><p><u>&nbsp;</u></p><p><u>Method of administration </u></p><p><u>&nbsp;</u></p><p>Oral use.</p><p><u>&nbsp;</u></p><p>Litfulo is to be taken once daily with or without food.</p><p>&nbsp;</p><p>Capsules should be swallowed whole and should not be crushed, split or chewed, because these methods of administration have not been studied in clinical trials.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1. 
•	Active serious infections, including tuberculosis (TB) (see section 4.4).
•	Severe hepatic impairment (see section 4.2).
•	Pregnancy and breast-feeding (see section 4.6).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Serious infections</u></p><p>&nbsp;</p><p>Serious infections have been reported in patients receiving ritlecitinib. The most frequent serious infections have been appendicitis, COVID-19 infection (including pneumonia), and sepsis. Treatment with ritlecitinib must not be initiated in patients with an active, serious infection (see section 4.3).</p><p>&nbsp;</p><p>The risks and benefits of treatment should be considered in patients:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with chronic or recurrent infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; who have been exposed to tuberculosis (TB)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with a history of serious or an opportunistic infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; who have resided or traveled in areas of endemic TB or mycoses, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with underlying conditions that may predispose them to infection</p><p>&nbsp;</p><p>Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with ritlecitinib. Treatment should be interrupted if a patient develops a serious or opportunistic infection. A patient who develops a new infection during treatment with ritlecitinib should undergo prompt and complete diagnostic testing appropriate for an immunocompromised patient, appropriate antimicrobial therapy should be initiated, and the patient should be closely monitored. If interrupted, ritlecitinib may be resumed once the infection is controlled.</p><p>&nbsp;</p><p>As there is a higher incidence of infections in elderly and in the diabetic population in general, caution should be exercised when treating the elderly and patients with diabetes, and particular attention paid with respect to occurrence of infections.</p><p>&nbsp;</p><p><em>Tuberculosis</em></p><p>Patients should be screened for TB before starting therapy with ritlecitinib. Ritlecitinib must not be given to patients with active TB (see section 4.3). Anti‑TB therapy should be started prior to initiating therapy with ritlecitinib in patients with a new diagnosis of latent TB or previously untreated latent TB. In patients with a negative latent TB test, anti‑TB therapy should still be considered before initiating treatment with ritlecitinib in those at high risk and screening for patients at high risk for TB during treatment with ritlecitinib should be considered.</p><p>&nbsp;</p><p><em>Viral reactivation</em></p><p>Viral reactivations, including cases of herpes virus reactivation (e.g., herpes zoster), have been reported (see section 4.8). If a patient develops herpes zoster, temporary interruption of treatment may be considered until the episode resolves.</p><p>&nbsp;</p><p>Screening for viral hepatitis should be performed in accordance with clinical guidelines before starting therapy with ritlecitinib. Patients with evidence of hepatitis B or C infection were excluded from studies with ritlecitinib. Monitoring for reactivation of viral hepatitis according to clinical guidelines is recommended during ritlecitinib treatment. If there is evidence of reactivation, a liver specialist should be consulted.</p><p>&nbsp;</p><p><u>Malignancy (including non‑melanoma skin cancer)</u></p><p>&nbsp;</p><p>Malignancies, including non‑melanoma skin cancer (NMSC) have been reported in patients receiving ritlecitinib.</p><p>&nbsp;</p><p>It is not known whether selective JAK3 inhibition may be associated with adverse reactions of Janus Kinase (JAK) inhibition predominantly involving JAK1 and JAK2. In a large randomised active‑controlled study of tofacitinib (another JAK inhibitor) in rheumatoid arthritis (RA) patients 50 years and older with at least one additional cardiovascular risk factor, a higher rate of malignancies, particularly lung cancer, lymphoma and NMSC, was observed with tofacitinib compared to tumour necrosis factor (TNF) inhibitors.</p><p>&nbsp;</p><p>Limited clinical data are available to assess the potential relationship of exposure to ritlecitinib and the development of malignancies. Long-term safety evaluations are ongoing. The risks and benefits of ritlecitinib treatment should be considered prior to initiating or continuing therapy in patients with a known malignancy other than a successfully treated NMSC or cervical cancer. &nbsp;</p><p>&nbsp;</p><p>Periodic skin examination is recommended for patients who are at increased risk of skin cancer.</p><p>&nbsp;</p><p><u>Major adverse cardiovascular events (MACE), deep venous thrombosis (DVT) and pulmonary embolism (PE)</u></p><p>&nbsp;</p><p>Events of venous and arterial thromboembolism, including MACE, have been reported in patients receiving ritlecitinib.</p><p>&nbsp;</p><p>It is not known whether selective JAK3 inhibition may be associated with adverse reactions of JAK inhibition predominantly involving JAK1 and JAK2. In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in RA patients 50 years and older with at least one additional cardiovascular risk factor, a higher rate of MACE, defined as cardiovascular death, non-fatal myocardial infarction and non-fatal stroke, and a dose‑dependent higher rate of venous thromboembolism including DVT and PE were observed with tofacitinib compared to TNF inhibitors.</p><p>&nbsp;</p><p>Long-term safety evaluations for ritlecitinib are ongoing. Ritlecitinib should be used with caution in patients with known risk factors for thromboembolism. In patients with a suspected thromboembolic event, discontinuation of ritlecitinib and prompt re‑evaluation is recommended. The risks and benefits of ritlecitinib treatment should be considered prior to initiating therapy in patients.</p><p><u>&nbsp;</u></p><p><u>Neurological events</u></p><p><em>&nbsp;</em></p><p>Ritlecitinib-related axonal dystrophy has been observed in chronic Beagle dog toxicity studies (see&nbsp;section 5.3). Treatment with ritlecitinib should be discontinued in case unexplained neurological symptoms occur.</p><p><u>&nbsp;</u></p><p><u>Haematologic abnormalities</u></p><p>&nbsp;</p><p>Treatment with ritlecitinib was associated with decreases in lymphocytes and platelets (see section 4.8). Prior to initiating treatment with ritlecitinib, ALC and platelet counts should be performed. Treatment with ritlecitinib should not be initiated in patients with an ALC &lt;&nbsp;0.5&nbsp;<strong>&times;&nbsp;</strong>10<sup>3</sup>/mm<sup>3</sup> or a platelet count &lt;&nbsp;100&nbsp;<strong>&times;&nbsp;</strong>10<sup>3</sup>/mm<sup>3</sup>. After initiating treatment with ritlecitinib, treatment interruption or discontinuation are recommended based on ALC and platelet count abnormalities (see section 4.2). ALC and platelet counts are recommended at 4 weeks after initiation of therapy with ritlecitinib, and thereafter according to routine patient management.</p><p>&nbsp;</p><p><u>Vaccinations</u></p><p>&nbsp;</p><p>No data are available on the response to vaccination in patients receiving ritlecitinib. Use of live attenuated vaccines should be avoided during or immediately prior to ritlecitinib treatment. Prior to initiating ritlecitinib, it is recommended that patients are brought up to date with all immunisations, including prophylactic herpes zoster vaccinations, in agreement with current immunisation guidelines.</p><p>&nbsp;</p><p><u>Elderly</u></p><p>&nbsp;</p><p>There are limited data in patients &ge;&nbsp;65 years of age. Age appeared to be a risk factor for lower ALC in patients &ge;&nbsp;65&nbsp;years of age.</p><p><em>&nbsp;</em></p><p><u>Excipients with known effect</u></p><p><u>&nbsp;</u></p><p><em>Lactose </em></p><p>Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose‑galactose malabsorption should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Potential for other medicinal products to affect the pharmacokinetics of ritlecitinib</u></p><p>&nbsp;</p><p>The coadministration of multiple 200&nbsp;mg doses of itraconazole, a strong CYP3A inhibitor, increased the area under curve (AUC)<sub>inf</sub> of ritlecitinib by approximately 15%. This is not considered clinically significant and, therefore dose adjustment is not required when ritlecitinib is coadministered with CYP3A inhibitors.</p><p>&nbsp;</p><p>The coadministration of multiple 600&nbsp;mg doses of rifampicin, a strong inducer of CYP enzymes, decreased the AUC<sub>inf</sub> of ritlecitinib by approximately 44%. This is not considered clinically significant and, therefore dose adjustment is not required when ritlecitinib is coadministered with inducers of CYP enzymes.</p><p>&nbsp;</p><p><u>Potential for ritlecitinib to affect the pharmacokinetics of other medicinal products</u></p><p>&nbsp;</p><p>Multiple doses of 200&nbsp;mg once daily ritlecitinib increased the AUC<sub>inf</sub> and C<sub>max</sub> of midazolam a CYP3A4 substrate, by approximately 2.7‑fold and 1.8‑fold, respectively. Ritlecitinib is a moderate inhibitor of CYP3A; caution should be exercised with concomitant use of ritlecitinib with CYP3A substrates (e.g., quinidine, cyclosporine, dihydroergotamine, ergotamine, pimozide) where moderate concentration changes may lead to serious adverse reactions. Dose adjustment recommendations for the CYP3A substrate (e.g., colchicine, everolimus, tacrolimus, sirolimus) should be considered.</p><p>&nbsp;</p><p>Multiple doses of 200&nbsp;mg once daily ritlecitinib increased the AUC<sub>inf</sub> and C<sub>max</sub> of caffeine, a CYP1A2 substrate, by approximately 2.7‑fold and 1.1‑fold, respectively. Ritlecitinib is a moderate inhibitor of CYP1A2; caution should be exercised with concomitant use of ritlecitinib with other CYP1A2 substrates (e.g., tizanidine) where moderate concentration changes may lead to serious adverse reactions. Dose adjustment recommendations for the CYP1A2 substrate (e.g., theophylline, pirfenidone) should be considered.</p><p>&nbsp;</p><p>The coadministration of a single 400&nbsp;mg dose of ritlecitinib increased the AUC<sub>inf</sub> of sumatriptan (an organic cation transporter [OCT]1 substrate) by approximately 1.3 to 1.5‑fold relative to sumatriptan dose given alone. The increase in sumatriptan exposure is not considered clinically relevant. Caution should be exercised with concomitant use of ritlecitinib with OCT1 substrates where small concentration changes may lead to serious adverse reactions.</p><p>&nbsp;</p><p>Ritlecitinib did not produce clinically significant changes in the exposures of oral contraceptives (e.g., ethinyl oestradiol or levonorgestrel), CYP2B6 substrates (e.g., efavirenz), CYP2C substrates (e.g., tolbutamide), or substrates of organic anion transporter (OAT)P1B1, breast cancer resistant protein (BCRP), and OAT3 (e.g., rosuvastatin).</p><p>&nbsp;</p><p><u>Pediatric population</u></p><p>&nbsp;</p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u></p><p>&nbsp;</p><p>Ritlecitinib is not recommended in women of childbearing potential not using contraception. Women of childbearing potential have to use effective contraception during treatment and for 1&nbsp;month following the final dose of Litfulo.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no or limited data from the use of ritlecitinib in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Ritlecitinib was teratogenic in rats and rabbits at high doses (see section 5.3). Litfulo is contraindicated during pregnancy (see section 4.3).</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>Available pharmacodynamic/toxicological data in animals have shown excretion of ritlecitinib in milk (see section 5.3). A risk to newborns/infants cannot be excluded. Litfulo is contraindicated during breast‑feeding (see section 4.3).</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>The effect of ritlecitinib on human fertility has not been evaluated. There were no effects on fertility in rats at clinically relevant exposures (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Litfulo has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The most frequently reported adverse reactions are diarrhoea (9.2%), acne (6.2%), upper respiratory tract infections (6.2%), urticaria (4.6%), rash (3.8%), folliculitis (3.1%), and dizziness (2.3%).</p><p><u>&nbsp;</u></p><p><u>Tabulated list of adverse reactions</u></p><p><u>&nbsp;</u></p><p>A total of 1630 patients were treated with ritlecitinib in placebo‑controlled studies of alopecia areata representing 2303&nbsp;patient‑years of exposure. Three placebo‑controlled studies were integrated (130&nbsp;participants on 50&nbsp;mg daily and 213&nbsp;participants on placebo) to evaluate the safety of ritlecitinib in comparison to placebo for up to 24&nbsp;weeks after treatment initiation.&nbsp;</p><p>&nbsp;</p><p>Table 2 lists all adverse reactions observed in alopecia areata placebo‑controlled studies presented by system organ class and frequency, using the following categories: very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&ge;&nbsp;1/1&nbsp;000 to &lt;&nbsp;1/100); rare (&ge;&nbsp;1/10&nbsp;000 to &lt;&nbsp;1/1&nbsp;000); very rare (&lt;&nbsp;1/10&nbsp;000). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p>Table 2.&nbsp;&nbsp;&nbsp;&nbsp; Adverse reactions</p><table border="1" cellspacing="0" cellpadding="0" style="width:624px"><thead><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Herpes zoster</p><p>Folliculitis</p><p>Upper respiratory tract infections</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Acne</p><p>Urticaria</p><p>Rash</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Blood creatine phosphokinase increased</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Platelet count decreased Lymphocyte count decreased</p><p>Alanine aminotransferase increased ˃ 3 &times; ULN<sup>a</sup></p><p>Aspartate aminotransferase increased ˃ 3 &times; ULN<sup>a</sup></p></td></tr></tbody></table><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Includes changes detected during laboratory monitoring</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><em>&nbsp;</em></p><p><em>Infections</em></p><p>In the placebo-controlled studies, for up to 24&nbsp;weeks, overall infections have been reported in 31% of patients (80.35 per 100 patient‑years) treated with placebo and 33% of patients (74.53 per 100&nbsp;patient‑years) treated with ritlecitinib 50&nbsp;mg. In study AA-I, for up to 48 weeks, overall infections were reported in 51% of patients (89.32 per 100 patient-years) treated with ritlecitinib 50 mg or higher.</p><p>&nbsp;</p><p>Among all patients treated with ritlecitinib in the integrated safety analysis, including the long‑term study and a study in vitiligo, overall infections were reported in 45.4% of patients (50.02 per 100&nbsp;patient‑years) treated with ritlecitinib 50&nbsp;mg or higher. Most infections were mild or moderate in severity.</p><p>&nbsp;</p><p>In the placebo-controlled studies the percentage of patients reporting infection‑related adverse reaction of herpes zoster were 1.5% in the ritlecitinib 50&nbsp;mg group compared to 0 in placebo. All herpes zoster events were non-serious; 1 patient receiving ritlecitinib 200/50&nbsp;mg (200&nbsp;mg once daily for 4 weeks followed by 50&nbsp;mg once daily) experienced an event of varicella zoster virus infection that met criteria as an opportunistic infection (multi‑dermatomal herpes zoster). In study AA-I, for up to 48 weeks, 2.3% of patients (2.61 per 100 patient-years) treated with ritlecitinib 50 mg or higher reported herpes zoster Among all patients treated with ritlecitinib in the integrated safety analysis, including the long‑term study and a study in vitiligo, the rate of herpes zoster was 1.10 per 100 patient-years in patients treated with ritlecitinib 50&nbsp;mg or higher.</p><p>&nbsp;</p><p>In the placebo‑controlled studies, for up to 24&nbsp;weeks, no serious infections were reported in patients treated with placebo or ritlecitinib 50&nbsp;mg. The proportion and rate of serious infections in patients treated with ritlecitinib 200/50&nbsp;mg was 0.9% (2.66 per 100&nbsp;patient‑years). In study AA-I, for up to 48&nbsp;weeks, serious infections were reported in 0.8% of patients (0.86 per 100 patient-years) treated with ritlecitinib 50 mg or higher. Among all patients treated with ritlecitinib in the integrated safety analysis, including the long‑term study and a study in vitiligo, the proportion and rate of serious infection in ritlecitinib 50&nbsp;mg or higher was 0.8% (0.59 per 100&nbsp;patient‑years).</p><p>&nbsp;</p><p><em>Opportunistic infections</em></p><p>Opportunistic infections of multi-dermatomal herpes zoster were reported in 1 patient (0.50 per 100&nbsp;patient‑years) treated with ritlecitinib 200/50&nbsp;mg in the placebo-controlled studies, no patients in study AA-I, for up to 48 weeks, and 2 patients (0.09 per 100&nbsp;patient‑years) treated with ritlecitinib 50&nbsp;mg or higher in the integrated safety analysis, including the long‑term study and a study in vitiligo. Cases of opportunistic herpes zoster were mild or moderate in severity.</p><p>&nbsp;</p><p><em>Decreased lymphocyte count</em></p><p>In the placebo‑controlled studies, for up to 24&nbsp;weeks, and study AA-I, for up to 48 weeks, treatment with ritlecitinib was associated with a decrease in lymphocyte count. Maximum effects on lymphocytes were observed within 4&nbsp;weeks, after which lymphocyte count remained stable at a lower level with continued therapy. Among all patients treated with ritlecitinib in the integrated safety analysis, including the long‑term study and a study in vitiligo, confirmed ALC &lt;&nbsp;0.5 <strong>&times;</strong> 10<sup>3</sup>/mm<sup>3</sup> occurred in 2 participants (&lt;&nbsp;0.1%) treated with ritlecitinib 50&nbsp;mg.</p><p><em>&nbsp;</em></p><p><em>Decreased platelet count</em></p><p>In the placebo‑controlled studies, for up to 24&nbsp;weeks, and study AA-I, for up to 48 weeks, treatment with ritlecitinib was associated with a decrease in platelet count. Maximum effects on platelets were observed within 4&nbsp;weeks, after which platelet count remained stable at a lower level with continued therapy. Among all patients treated with ritlecitinib in the integrated safety analysis, including the long‑term study and a study in vitiligo, 1&nbsp;patient (&lt;&nbsp;0.1%) treated with ritlecitinib 50&nbsp;mg or higher had a confirmed platelet count &lt;&nbsp;100&nbsp;<strong>&times;&nbsp;</strong>10<sup>3</sup>/mm<sup>3</sup>.</p><p><em>&nbsp;</em></p><p><em>Creatine </em><em>phosphokinase (CPK) elevations </em></p><p>In the placebo‑controlled studies, for up to 24&nbsp;weeks, events of blood CPK increased were reported in 2&nbsp;patients (1.5%) treated with ritlecitinib 50&nbsp;mg. In study AA-I, for up to 48 weeks, events of blood CPK increased were reported in 3.8% of patients treated with ritlecitinib 50 mg or higher. CPK elevations &gt;5x upper limit of normal (ULN) were reported in 2 (0.9%) of patients treated with placebo and 5 (3.9%) of patients treated with ritlecitinib 50 mg. In study AA-I, for up to 48 weeks, CPK elevations &gt;5x ULN were reported in 6.6% of patients treated with ritlecitinib 50 mg or higher. Most elevations were transient and none led to discontinuation.</p><p>&nbsp;</p><p><em>Increased transaminases </em></p><p>In the placebo‑controlled studies, for up to 24&nbsp;weeks, events of increases in ALT and AST values (&gt;3&nbsp;&times; ULN) were reported in 3 patients (0.9%) and 2 patients (0.6%) treated with ritlecitinib 50 mg or higher, respectively. Most elevations were transient, and none led to discontinuation.</p><p>&nbsp;</p><p><u>Pediatric population</u></p><p>&nbsp;</p><p>A total of 181&nbsp;adolescents (12&nbsp;to &lt;&nbsp;18&nbsp;years of age) were enrolled in ritlecitinib alopecia areata placebo‑controlled studies.</p><p>&nbsp;</p><p>The safety profile observed in adolescents was similar to that of the adult population.</p><p><strong><em>&nbsp;</em></strong></p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via National Pharmacovigilance Centre (NPC).</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp; Call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ritlecitinib was administered in placebo‑controlled studies up to a single oral dose of 800&nbsp;mg and multiple oral doses of 400 mg daily for 14 days. No specific toxicities were identified. In case of overdose, it is recommended that the patient be monitored for signs and symptoms of adverse reactions (see section 4.8). There is no specific antidote for overdose with ritlecitinib. Treatment should be symptomatic and supportive.</p><p>&nbsp;</p><p>Pharmacokinetics (PK) data up to and including a single oral dose of 800&nbsp;mg in healthy adult volunteers indicate that more than 90% of the administered dose is expected to be eliminated within 48&nbsp;hours.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Immunosuppressants, Janus-associated kinase (JAK) inhibitors, ATC code: L04AF08</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Ritlecitinib irreversibly and selectively inhibits Janus kinase (JAK) 3 and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) family by blocking the adenosine triphosphate (ATP) binding site. In cellular settings, ritlecitinib specifically inhibits &gamma;-common cytokines (IL-2, IL-4, IL-7, IL-15 and IL-21) signalling through JAK3-dependent common-&gamma; chain receptors. Additionally, ritlecitinib inhibits TEC family of kinases, resulting in reduced cytolytic activity of NK cells and CD8+ T cells.</p><p>&nbsp;</p><p>JAK3 and TEC family mediated signalling pathways are both involved in alopecia areata pathogenesis, although complete pathophysiology is still not understood.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p><u>&nbsp;</u></p><p><em>Lymphocyte subsets</em></p><p>In patients with alopecia areata, treatment with ritlecitinib was associated with dose-dependent early decreases in absolute lymphocyte levels, T lymphocytes (CD3) and T lymphocyte subsets (CD4 and CD8). After the initial decrease, the levels partially recovered and remained stable up to 48&nbsp;weeks. There was no change observed in B lymphocytes (CD19) in any treatment group. There was a dose‑dependent early decrease in NK cells (CD16/56) which remained stable at the lower level up to Week 48.</p><p><em>&nbsp;</em></p><p><em>Immunoglobulins</em></p><p>In patients with alopecia areata, treatment with ritlecitinib was not associated with clinically meaningful changes in Immunoglobulin (Ig)G, IgM or IgA up to Week 48, indicating a lack of systemic humoral immunosuppression.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p>The efficacy and safety of ritlecitinib was evaluated in a pivotal, randomised, double‑blind, placebo‑controlled study (study AA-I) in alopecia areata patients 12&nbsp;years of age and older with &ge;&nbsp;50% scalp hair loss, including alopecia totalis and alopecia universalis. The dose‑response of ritlecitinib was also evaluated in this study. The study treatment period consisted of a placebo‑controlled 24‑week period and a 24‑week extension period. Study AA‑I evaluated a total of 718&nbsp;patients who were randomised to one of the following treatment regimens for 48&nbsp;weeks: 1) 200&nbsp;mg once daily for 4 weeks followed by 50&nbsp;mg once daily for 44&nbsp;weeks; 2) 200&nbsp;mg once daily for 4&nbsp;weeks followed by 30&nbsp;mg once daily for 44&nbsp;weeks; 3) 50&nbsp;mg once daily for 48&nbsp;weeks; 4) 30&nbsp;mg once daily for 48&nbsp;weeks; 5) 10&nbsp;mg once daily for 48&nbsp;weeks; 6) placebo for 24&nbsp;weeks followed by 200&nbsp;mg once daily for 4&nbsp;weeks and 50&nbsp;mg once daily for 20&nbsp;weeks; or 7) placebo for 24&nbsp;weeks followed by 50&nbsp;mg for 24&nbsp;weeks.</p><p>&nbsp;</p><p>This study assessed as primary outcome the proportion of subjects who achieved a SALT (Severity of Alopecia Tool) score of &le;&nbsp;10 (90% or more scalp hair coverage) at Week&nbsp;24. Additionally, this study assessed as key secondary outcome the Patient&rsquo;s Global Impression of Change (PGI-C) response at Week&nbsp;24 and also assessed as secondary outcomes SALT score of &le;&nbsp;20 (80% or more scalp hair coverage) at Week 24 and improvements in regrowth of eyebrows and/or eyelashes at Week&nbsp;24.</p><p>&nbsp;</p><p><em>Baseline characteristics</em></p><p>Male or female patients 12&nbsp;years of age and older, were assessed in study AA‑I. All patients had alopecia areata with &ge;&nbsp;50% scalp hair loss (SALT [Severity of Alopecia Tool] score &ge;&nbsp;50) without evidence of terminal hair regrowth within the previous 6&nbsp;months and with the current episode of scalp hair loss &le;&nbsp;10 years and no other known cause of hair loss (e.g., androgenetic alopecia).</p><p>&nbsp;</p><p>Across all treatment groups 62.1% were female, 68.0% were White, 25.9% were Asian, and 3.8% were Black or African American. The mean age of patients was 33.7 years and the majority (85.4%) were adults (&ge;&nbsp;18 years of age). A total of 105 (14.6%) patients 12 to &lt;&nbsp;18 years of age and 20 (2.8%) patients 65&nbsp;years of age and older were enrolled. The mean (SD) baseline absolute SALT score ranged from 88.3 (16.87) to 93.0 (11.50) across treatment groups; among patients without alopecia totalis/alopecia universalis at baseline, the mean SALT score ranged from 78.3 to 87.0. The majority of patients had abnormal eyebrows (83.0%) and eyelashes (74.7%) at baseline across treatment groups. The median duration since alopecia areata diagnosis was 6.9&nbsp;years and the median duration of the current alopecia areata episode was 2.5&nbsp;years. Randomisation was stratified by alopecia totalis/alopecia universalis status with 46% of patients classified as alopecia totalis/alopecia universalis based upon a baseline SALT score of 100.</p><p>&nbsp;</p><p><em>Clinical response</em></p><p>A significantly greater proportion of patients achieved SALT &le;&nbsp;10 response with ritlecitinib 50&nbsp;mg compared to placebo at Week&nbsp;24 (Table 3). The SALT &le;&nbsp;10 response rate for ritlecitinib 50&nbsp;mg increased further at Week&nbsp;48 (Figure 1).</p><p>&nbsp;</p><p>A significantly greater proportion of patients achieved Patient&rsquo;s Global Impression of Change (PGI-C) response with ritlecitinib 50&nbsp;mg compared to placebo at Week&nbsp;24 (Table 3) with response rates continuing to increase through Week&nbsp;48 (Figure 1).</p><p>&nbsp;</p><p>A significantly greater proportion of patients achieved a SALT &le;&nbsp;20 response with ritlecitinib 50&nbsp;mg compared to placebo at Week&nbsp;24 (Table&nbsp;3). The SALT &le;&nbsp;20 response rate increased further at Week&nbsp;48.</p><p>&nbsp;</p><p>Improvements in regrowth of eyebrows and/or eyelashes were seen at Week&nbsp;24 (Table 3) with ritlecitinib 50&nbsp;mg among patients with abnormal eyebrows and/or eyelashes at baseline with further increases seen at Week&nbsp;48.</p><p>&nbsp;</p><p>Treatment effects at Week 24 in subgroups (age, gender, race, region, weight, duration of disease since diagnosis, duration of current episode, prior pharmacologic treatment) were consistent with the results in the overall study population. Treatment effects at Week 24 in the alopecia totalis/alopecia universalis subgroup were lower compared to the non-alopecia totalis/non-alopecia universalis subgroup. Treatment effects at Week 24 in adolescents 12 to less than 18 years of age were consistent with the results in the overall study population.</p><p>&nbsp;</p><p><strong>Table 3.</strong>&nbsp;&nbsp;&nbsp; <strong>Efficacy results of ritlecitinib at week 24</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>Ritlecitinib 50 mg once daily</strong></p><p><strong>(N = 130)</strong></p><p><strong>% Responders</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>(N = 131)</strong></p><p><strong>% Responders</strong></p></td><td style="vertical-align:top"><p><strong>Difference from </strong></p><p><strong>placebo </strong></p><p><strong>(95% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>SALT &le;&nbsp;10 response<sup>a,b</sup></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>13.4</p></td><td style="vertical-align:top"><p>1.5</p></td><td style="vertical-align:top"><p>11.9</p><p>(5.4, 18.3)</p></td></tr><tr><td style="vertical-align:top"><p>PGI‑C response<sup>b,c</sup></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>49.2</p></td><td style="vertical-align:top"><p>9.2</p></td><td style="vertical-align:top"><p>40.0</p><p>(28.9, 51.1)</p></td></tr><tr><td style="vertical-align:top"><p>SALT &le;&nbsp;20 response<sup>d,e</sup></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>23.0</p></td><td style="vertical-align:top"><p>1.6</p></td><td style="vertical-align:top"><p>21.4</p><p>(13.4, 29.5)</p></td></tr><tr><td style="vertical-align:top"><p>EBA response<sup>f</sup></p></td><td style="vertical-align:top"><p>29.0</p></td><td style="vertical-align:top"><p>4.7</p></td><td style="vertical-align:top"><p>24.3</p><p>(14.8, 34.5)</p></td></tr><tr><td style="vertical-align:top"><p>ELA response<sup>g</sup></p></td><td style="vertical-align:top"><p>28.9</p></td><td style="vertical-align:top"><p>5.2</p></td><td style="vertical-align:top"><p>23.7</p><p>(13.6, 34.5)</p></td></tr></tbody></table><p>Abbreviations: EBA = eyebrow assessment; ELA = eyelash assessment; CI = confidence interval; N = total number of patients; PGI‑C = Patient&rsquo;s Global Impression of Change; SALT = Severity of Alopecia Tool</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SALT &le;&nbsp;10 responders were patients with scalp hair loss of &le;&nbsp;10%. SALT scores range from 0 to 100 with 0&nbsp;=&nbsp;no scalp hair loss and 100 = total scalp hair loss.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Statistically significant with adjustment for multiplicity.</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PGI-C responders were patients with a score of &ldquo;moderately improved&rdquo; or &ldquo;greatly improved&rdquo; based upon a 7‑point scale from &ldquo;greatly improved&rdquo; to &ldquo;greatly worsened&rdquo;.</p><p>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SALT &le;&nbsp;20 responders were patients with scalp hair loss of &le;&nbsp;20%. SALT scores range from 0 to 100 with 0&nbsp;=&nbsp;no scalp hair loss and 100 = total scalp hair loss.</p><p>e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Statistically significant.</p><p>f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EBA response is defined as at least a 2‑grade improvement from baseline or normal EBA score on a 4‑point scale in patients with abnormal eyebrows at baseline.</p><p>g.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ELA response is defined as at least a 2‑grade improvement from baseline or normal ELA score on a 4‑point scale in patients with abnormal eyelashes at baseline.</p><p><strong>&nbsp;</strong></p><p><strong>Figure 1.</strong>&nbsp;&nbsp;&nbsp; <strong>SALT &le;&nbsp;10 and PGI-C response through Week 48</strong></p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_9" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:471pt;height:156.75pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/bakhsm/AppData/Local/Temp/2/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="628" height="209" src="file:///C:/Users/bakhsm/AppData/Local/Temp/2/msohtmlclip1/01/clip_image002.jpg" /></p><p>Abbreviations: CI = confidence interval; N = total number of patients; PGI-C = Patient Global Impression of Change; QD = once daily; SALT = Severity of Alopecia Tool</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with ritlecitinib in one or more subsets of the pediatric population in the treatment of alopecia areata (see section 4.2 for information on pediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>&nbsp;</p><p>The absolute oral bioavailability of ritlecitinib is about 64%. Based on oral and intravenous administration of the labelled active substance, the relative urinary recovery (oral/intravenous) of labelled compounds was about 89%, indicating a high fraction absorbed (f<sub>a</sub>). Peak plasma concentrations are reached within 1&nbsp;hour following multiple oral doses. Food does not have a clinically significant impact on the extent of ritlecitinib absorption, as a high‑fat meal decreased the ritlecitinib C<sub>max</sub> by ~&nbsp;32% and increased AUC<sub>inf</sub> by ~11%. In placebo‑controlled studies, ritlecitinib was administered without regard to meals (see section 4.2).<em> </em></p><p><em>&nbsp;</em></p><p><em>In vitro</em>, ritlecitinib is a substrate of P‑glycoprotein (P‑gp) and BCRP. However, as ritlecitinib has a high fraction absorbed (f<sub>a</sub>) with both C<sub>max</sub> and AUC increases in a dose proportional manner (20 &ndash; 200&nbsp;mg single dose range), P‑gp and BCRP are not expected to have a meaningful impact on the absorption of ritlecitinib.</p><p><u>&nbsp;</u></p><p><u>Distribution</u></p><p>&nbsp;</p><p>After intravenous administration, the volume of distribution of ritlecitinib is about 74&nbsp;L. Approximately 14% of circulating ritlecitinib is bound to plasma proteins, primarily albumin. The blood/plasma distribution ratio of ritlecitinib is 1.62. Ritlecitinib is a covalent inhibitor that has been shown to bind to off‑target proteins such as MAP2K7, DOCK10, albumin, CYP1A2, CYP3A, UGT1A1, and UGT1A4, some of which may have clinical relevance in drug interactions (see section&nbsp;4.5).</p><p><u>&nbsp;</u></p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>The metabolism of ritlecitinib is mediated by multiple isoforms of Glutathione S‑transferase (GST: cytosolic GST A1/3, M1/3/5, P1, S1, T2, Z1, and microsomal Membrane Associated Proteins involved in Eicosanoid and Glutathione metabolism [MAPEG]1/2/3) and CYP enzymes (CYP3A, CYP2C8, CYP1A2, and CYP2C9), with no single clearance route contributing more than 25%. Hence, medicinal products inhibiting a selective metabolic pathway are unlikely to impact the systemic exposures of ritlecitinib. Specific inhibitors of transporters are unlikely to result in clinically relevant changes in the bioavailability of ritlecitinib.</p><p>&nbsp;</p><p>In a human radiolabeled study, ritlecitinib was the most prevalent circulating species (30.4% of circulating radioactivity) after oral administration, with a major cysteine conjugate metabolite M2 (16.5%), which is pharmacologically inactive.</p><p><u>&nbsp;</u></p><p><u>Elimination</u></p><p>&nbsp;</p><p>Ritlecitinib is eliminated primarily by metabolic clearance mechanisms, with approximately 4% of the dose excreted as unchanged active substance in urine. Approximately 66% of radiolabeled ritlecitinib dose is excreted in the urine and 20% in the faeces. Following multiple oral doses, steady state was reached approximately by Day 4 due to non‑stationary PK. The steady state PK parameters of AUC<sub>tau</sub> and C<sub>max</sub> appeared to increase in an approximately dose‑proportional manner up to 200 mg with the mean terminal half‑life ranging from 1.3 to 2.3 hours.</p><p><u>&nbsp;</u></p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Body weight, gender, genotype, race and age </em></p><p>Body weight, gender, GST P1, M1, and T1 genotype, race and age did not have a clinically meaningful effect on ritlecitinib exposure.</p><p><em>&nbsp;</em></p><p><em>Adolescents (&ge;&nbsp;12 to &lt;&nbsp;18&nbsp;years)</em></p><p>Based on population PK analysis, there was no clinically relevant difference in ritlecitinib exposures in adolescent patients compared to adults.</p><p><em>&nbsp;</em></p><p><em>Pediatric (&lt;&nbsp;12&nbsp;years)</em></p><p>The PK of ritlecitinib in children under 12&nbsp;years of age have not yet been established.</p><p><em>&nbsp;</em></p><p><u>Renal impairment</u><em> </em></p><p>&nbsp;</p><p>The AUC<sub>24</sub> and C<sub>max</sub> in patients with severe renal impairment (estimated glomerular filtration rate [eGFR] &lt;&nbsp;30 mL/min) was about 55% and 44% higher, respectively, compared with matched participants with normal renal functions. This was confirmed by popPK analysis. These differences are not considered clinically significant. Ritlecitinib was not studied in patients with mild (eGFR 60 to &lt;&nbsp;90&nbsp;mL/min) or moderate (eGFR 30 to &lt;&nbsp;60&nbsp;mL/min) renal impairment. However, based on the results obtained in patients with severe renal impairment, a clinically significant increase in ritlecitinib exposure is not expected in these patients. The eGFR and classification of renal function status of participants was done using the Modification of Diet in Renal Disease (MDRD) formula.</p><p>&nbsp;</p><p>Based on the above considerations, no dose adjustment is required in patients with mild, moderate or severe renal impairment. Ritlecitinib has not been studied in patients with ESRD or in renal transplant recipients (see section 4.2).</p><p>&nbsp;</p><p><u>Hepatic impairment</u><em> </em></p><p>&nbsp;</p><p>Patients with moderate (Child Pugh B) hepatic impairment had an 18.5% increase in ritlecitinib AUC<sub>24</sub> compared to participants with normal hepatic function. Ritlecitinib was not studied in patients with mild (Child Pugh A) hepatic impairment. However, based on the results obtained in patients with moderate hepatic impairment, a clinically significant increase in ritlecitinib exposure is not expected in these patients. No dose adjustment is required in patients with mild or moderate hepatic impairment (see section 4.2). Ritlecitinib has not been studied in patients with severe (Child Pugh C) hepatic impairment (see section 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General toxicity</u></p><p><u>&nbsp;</u></p><p>Decreased lymphocyte counts and decreased lymphoid cellularity of organs and tissues of the immune and haematolymphopoietic systems were observed in nonclinical toxicity studies and were attributed to the pharmacological properties (JAK3/TEC inhibition) of ritlecitinib.</p><p>&nbsp;</p><p>Chronic administration of ritlecitinib to Beagle dogs led to the occurrence of axonal dystrophy at systemic exposures of at least 7.4-times the expected exposure in patients treated with 50 mg per day (based on unbound AUC24). Axonal dystrophy is presumably related to binding to off-target neuronal proteins. It is not known if axonal dystrophy occurred in dogs at lower systemic exposures. At a systemic exposure that was 33-times above the expected exposure in patients treated with 50 mg per day (based on unbound AUC24), axonal dystrophy was associated with neurological hearing loss. While these findings proved to reverse after dosing cessation of ritlecitinib in dogs, a risk to patients at a chronic dosing regimen cannot be fully excluded (see section 4.4).</p><p><u>&nbsp;</u></p><p><u>Genotoxicity</u></p><p>&nbsp;</p><p>Ritlecitinib was not mutagenic in the bacterial mutagenicity assay (Ames assay). Ritlecitinib is not aneugenic or clastogenic at exposures equal to 130&nbsp;times the MRHD on an unbound AUC basis based on the results of the <em>in vivo</em> rat bone marrow micronucleus assay.</p><p>&nbsp;</p><p><u>Carcinogenicity</u></p><p>&nbsp;</p><p>No evidence of tumorigenicity was observed in the 6‑month Tg.ras H2 mice administered ritlecitinib at exposures equal to 11 times the MRHD on an unbound AUC basis. In a 2‑year rat carcinogenicity study, a higher incidence of benign thymomas in female rats and benign thyroid follicular adenomas in male rats was noted following ritlecitinib administration at exposures equal to 29&nbsp;times the MRHD on an unbound AUC basis. At this ritlecitinib exposure, a higher incidence of malignant thymomas in female rats cannot be excluded. No ritlecitinib‑related thymomas or thyroid follicular adenomas were observed at exposures equal to 6.3&nbsp;times the MRHD on an unbound AUC basis.</p><p>&nbsp;</p><p><u>Reproductive and developmental toxicity</u></p><p>&nbsp;</p><p>Ritlecitinib had no effects on female rat fertility at exposures equal to 55&nbsp;times the MRHD on an unbound AUC basis. Effects on male rat fertility were noted (higher preimplantation loss resulting in lower number of implantation sites and corresponding lower litter size in na&iuml;ve females mated with ritlecitinib dosed males) at exposure equal to 55&nbsp;times the MRHD on an unbound AUC basis. No effects on male fertility were noted at exposures equal to 14&nbsp;times the MRHD on an unbound AUC basis. No effects on spermatogenesis (sperm counts, sperm production rate, motility, and morphology) were noted at any dose in the rat fertility study.</p><p>&nbsp;</p><p>In an embryo‑foetal development study in pregnant rats, oral administration of ritlecitinib from gestation days 6 to 17 resulted in foetal skeletal malformations and variations and lower foetal body weights at exposures greater than or equal to 49&nbsp;times the unbound AUC at the MRHD (see section 4.3). There were no effects on embryo‑foetal development at exposures equal to 16&nbsp;times the unbound AUC at the MRHD.</p><p>&nbsp;</p><p>In an embryo‑foetal development study in pregnant rabbits, oral administration of&nbsp;ritlecitinib&nbsp;from gestation days 7 to 19 resulted in lower mean foetal body weights and higher incidences of visceral malformations, skeletal malformations, and skeletal variations at exposures equal to 55&nbsp;times the unbound AUC at the MRHD (see section 4.3). There were no effects on embryo‑foetal development at exposures equal to 12&nbsp;times the unbound AUC at the MRHD.</p><p>&nbsp;</p><p>In a rat pre- and postnatal development study, oral administration of ritlecitinib from gestation day&nbsp;6 through lactation day&nbsp;20 resulted in developmental toxicity that included lower postnatal survival, lower offspring body weights, and secondary developmental delays at exposure equal to 41&nbsp;times the unbound AUC at the MRHD (see section 4.3). Bred females in the F1 generation exhibited lower mean numbers of corpora lutea at exposures equal to 41&nbsp;times the unbound AUC at the MRHD. There were no effects on pre‑ and postnatal development at exposures equal to 14&nbsp;times the unbound AUC at the MRHD.</p><p>&nbsp;</p><p>In a juvenile rat toxicity study, oral administration of ritlecitinib from postnatal day 10 to 60 (comparable to infant through adolescence human age) was not associated with effects on the nervous or skeletal systems.</p><p>&nbsp;</p><p><u>Lactation</u></p><p>&nbsp;</p><p>Following administration of ritlecitinib to lactating rats, concentrations of ritlecitinib in milk over time were higher than those in plasma, where the mean milk to plasma AUC ratio was determined to be 2.2 (see section 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hard capsule content</u></p><p>&nbsp;</p><p>Cellulose microcrystalline</p><p>Lactose monohydrate</p><p>Crospovidone</p><p>Glycerol dibehenate</p><p>&nbsp;</p><p><u>Hard capsule</u><u> shell</u></p><p>&nbsp;</p><p>Hypromellose (E464)</p><p>Titanium dioxide (E171)</p><p>Yellow iron oxide (E172)</p><p>Brilliant Blue FCF (E133)</p><p>&nbsp;</p><p><u>Printing ink</u></p><p>&nbsp;</p><p>Shellac</p><p>Propylene glycol</p><p>Ammonia solution concentrated</p><p>Black iron oxide (E172)</p><p>Potassium hydroxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store LITFULO below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>OPA/Al/PVC/Al blisters containing 10&nbsp;hard capsules. Each pack contains 30 hard capsules.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorization Holder
Pfizer Inc.
New York, USA

Manufacturer
Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ..
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>